| Name | Title | Contact Details |
|---|
Launched in April 2020, Talkiatry provides accessible in-network psychiatric care. The technology-driven service is committed to providing the highest level of mental health care on an outpatient basis. Based in New York City, Talkiatry offers seamless telehealth as well as in-person care in thoughtfully-designed, upscale offices—all at affordable, in-network prices. Talkiatry accepts a wide-range of insurance and employs psychiatrists and psychiatric nurse practitioners curated from among the city`s finest healthcare providers.
Alfa Aesar, a Johnson Matthey Company, is a leading international manufacturer and supplier of research chemicals, metals and materials. With 30,000 products listed in the catalogue, Alfa Aesar is the single source for customers' chemical and material
Columbia Wellness is a first-class mental health, substance use disorder, and acute detox provider in Cowlitz & Grays Harbor County with offices in Longview, Kelso, Woodland, Aberdeen and Hoquiam, WA
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of phyto-therapeutics, commonly known as plant-made solutions. We are committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for our patients.
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.